Avandia’s labeling information revised
PHILADELPHIA — GlaxoSmithKline has changed prescribing information on the labeling for one of its Type 2 diabetes drugs to reflect new restrictions on the drug’s use, the drug maker said.
GSK said it revised the labeling for Avandia (rosiglitazone) to take into account the risks of heart attacks and heart failure in patients taking the drug.
The FDA moved to restrict access to Avandia last year and required GSK to create a risk evaluation and mitigation strategy for the drug.
This label change is long overdue. Many patients lives could have been saved if this warning was placed when GSK knew of the problems related to MI's, CHF and Strokes. It is now GSK's responsibility to pay damages to those who have suffered from this medication.
Gilead resubmits HIV drug application to FDA
FOSTER CITY, Calif. — Gilead Sciences has refiled an approval application with the Food and Drug Administration for an HIV drug, the drug maker said.
Gilead said it had resubmitted its application for a single-tablet combination of Truvada (emtricitabine and tenofovir disoproxil fumarate) and Johnson & Johnson subsidiary Tibotec Pharmaceuticals’ investigational drug TMC278 (rilpivirine hydrochloride) to treat HIV-1 infection in adults.
Gilead had submitted its application for the drug in November 2010, but the FDA issued a “refuse to file” notification, requesting additional information on the analytical methodology and qualification data used to establish acceptable levels of recently identified degradants related to emtricitabine.
No comments found
Report: Generic drug makers may look to diversify portfolios
PHILADELPHIA — An increase in consolidation among generic drug companies could be in the works, according to a new report from Thomson Reuters.
According to the report, “Gaining Market Share in the Generic Drug Industry Through Acquisitions and Partnerships,” generic drug makers face competition, as well as government-mandated price cuts in Europe and such policies as lowest-price tendering. As a result, many could seek deals that would cause them to diversify their portfolios.
“Pricing pressures in established generics markets have forced the industry to look for economies of scale in manufacturing and opportunities in emerging markets,” Thomson Reuters Generics and API intelligence director Kate Kuhrt said. “Companies also are cutting out the middleman and diversifying their product portfolios by moving into niche areas, including follow-on biologics.”
The number of companies that have the follow-on biologics option is limited to those that can afford the high development costs, which can range from $100 million to $200 million, compared with $1 million to $5 million for generic pharmaceuticals. Teva Pharmaceutical Industries, Sandoz and Hospira already make follow-on biologics for the European market, and Teva has sought to make inroads into the impending U.S. market as well.
Meanwhile, such companies as Mylan and Watson Pharmaceuticals have expressed interest — Watson set itself up to enter the market with its 2009 acquisition of Arrow Group — as have such branded drug makers as Merck.
Despite the projected increase in consolidation, mergers and acquisitions lately have decreased, from $24 billion in 2008 to $6.8 billion in 2009, according to the report.
No comments found